CA2187128A1 - Polymorphe nouveau et efficace, a base de chlorhydrate de paroxetine anhydre - Google Patents

Polymorphe nouveau et efficace, a base de chlorhydrate de paroxetine anhydre

Info

Publication number
CA2187128A1
CA2187128A1 CA002187128A CA2187128A CA2187128A1 CA 2187128 A1 CA2187128 A1 CA 2187128A1 CA 002187128 A CA002187128 A CA 002187128A CA 2187128 A CA2187128 A CA 2187128A CA 2187128 A1 CA2187128 A1 CA 2187128A1
Authority
CA
Canada
Prior art keywords
paroxetine hydrochloride
form iii
anhydrous
paroxetine
schedule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002187128A
Other languages
English (en)
Inventor
K. S. Keshava Murthy
Allan Rey
Gamini Weeratunga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apotex Pharmachem Inc
Original Assignee
Brantford Chemicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brantford Chemicals Inc filed Critical Brantford Chemicals Inc
Priority to CA002187128A priority Critical patent/CA2187128A1/fr
Publication of CA2187128A1 publication Critical patent/CA2187128A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002187128A 1996-10-04 1996-10-04 Polymorphe nouveau et efficace, a base de chlorhydrate de paroxetine anhydre Abandoned CA2187128A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002187128A CA2187128A1 (fr) 1996-10-04 1996-10-04 Polymorphe nouveau et efficace, a base de chlorhydrate de paroxetine anhydre

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002187128A CA2187128A1 (fr) 1996-10-04 1996-10-04 Polymorphe nouveau et efficace, a base de chlorhydrate de paroxetine anhydre

Publications (1)

Publication Number Publication Date
CA2187128A1 true CA2187128A1 (fr) 1997-06-26

Family

ID=4159025

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002187128A Abandoned CA2187128A1 (fr) 1996-10-04 1996-10-04 Polymorphe nouveau et efficace, a base de chlorhydrate de paroxetine anhydre

Country Status (1)

Country Link
CA (1) CA2187128A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874447A (en) * 1997-06-10 1999-02-23 Synthon B. V. 4-Phenylpiperidine compounds for treating depression
WO1999032484A1 (fr) * 1997-12-19 1999-07-01 Smithkline Beecham Plc Procede de preparation d'hydrochlorure de paroxetine
WO2000001693A1 (fr) * 1998-07-07 2000-01-13 Medichem, S.A. Polymorphe de maleate de paroxetine et formulations pharmaceutiques le contenant
US6063927A (en) * 1998-07-02 2000-05-16 Smithkline Beecham Plc Paroxetine derivatives
WO2000032592A1 (fr) * 1998-11-28 2000-06-08 Smithkline Beecham Plc Procede de fabrication d'hydrochlorure de paroxetine
WO2001012623A1 (fr) * 1999-08-12 2001-02-22 Smithkline Beecham P.L.C. Procede de preparation d'hydrochlorure de paroxetine anhydre
US6436956B1 (en) 1996-12-24 2002-08-20 Brantford Chemicals Inc. Useful form of anhydrous paroxetine hydrochloride
WO2002102382A1 (fr) * 2001-06-14 2002-12-27 Teva Pharmaceutical Industries Ltd. Procede de preparation de paroxetine hcl limitant la formation de composes colores en rose
WO2005019209A2 (fr) * 2003-06-12 2005-03-03 Cadila Healthcare Limited Nouvelle forme d'hydrochlorure de paroxetine anhydre et son procede de preparation

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436956B1 (en) 1996-12-24 2002-08-20 Brantford Chemicals Inc. Useful form of anhydrous paroxetine hydrochloride
US6900327B2 (en) 1997-06-10 2005-05-31 Synthon Bct Technologies, Llc 4-phenylpiperidine compounds
US5874447A (en) * 1997-06-10 1999-02-23 Synthon B. V. 4-Phenylpiperidine compounds for treating depression
US7598271B1 (en) 1997-06-10 2009-10-06 Noven Therapeutics, Llc Crystalline paroxetine methane sulfonate
WO1999032484A1 (fr) * 1997-12-19 1999-07-01 Smithkline Beecham Plc Procede de preparation d'hydrochlorure de paroxetine
US6063927A (en) * 1998-07-02 2000-05-16 Smithkline Beecham Plc Paroxetine derivatives
WO2000001693A1 (fr) * 1998-07-07 2000-01-13 Medichem, S.A. Polymorphe de maleate de paroxetine et formulations pharmaceutiques le contenant
ES2138937A1 (es) * 1998-07-07 2000-01-16 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
US6440459B1 (en) 1998-07-07 2002-08-27 Medichem, S.A. Paroxetine maleate polymorph and pharmaceutical compositions containing it
WO2000032592A1 (fr) * 1998-11-28 2000-06-08 Smithkline Beecham Plc Procede de fabrication d'hydrochlorure de paroxetine
WO2001012623A1 (fr) * 1999-08-12 2001-02-22 Smithkline Beecham P.L.C. Procede de preparation d'hydrochlorure de paroxetine anhydre
WO2002102382A1 (fr) * 2001-06-14 2002-12-27 Teva Pharmaceutical Industries Ltd. Procede de preparation de paroxetine hcl limitant la formation de composes colores en rose
WO2005019209A3 (fr) * 2003-06-12 2005-05-12 Cadila Healthcare Ltd Nouvelle forme d'hydrochlorure de paroxetine anhydre et son procede de preparation
WO2005019209A2 (fr) * 2003-06-12 2005-03-03 Cadila Healthcare Limited Nouvelle forme d'hydrochlorure de paroxetine anhydre et son procede de preparation

Similar Documents

Publication Publication Date Title
US4721723A (en) Anti-depressant crystalline paroxetine hydrochloride hemihydrate
AU604553B2 (en) Azithromycin dihydrate
US6429210B1 (en) Polymorphic clopidogrel hydrogenesulphate form
WO2006024863A1 (fr) Forme cristalline stable d'imatinib mesylate et son procede de preparation
SK285303B6 (sk) Modifikácie 2-amino-4-(4-fluórbenzylamino)-1- etoxykarbonylaminobenzénu, spôsob ich prípravy, ich použitie a liečivá s ich obsahom
CZ289730B6 (cs) Krystalický hydrochlorid (R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-budyl]-aminomethyl}-chromanu, způsob jeho výroby, farmaceutický prostředek tuto látku obsahující a její pouľití
EP0579681B1 (fr) Monohydrate d'hydrochlorure de tiagabine cristalline, sa preparation et son utilisation
CA2187128A1 (fr) Polymorphe nouveau et efficace, a base de chlorhydrate de paroxetine anhydre
JPH03141283A (ja) ２３―（ｃ↓１―ｃ↓６アルキルオキシム）―ｌｌ―ｆ２８２４９化合物の製造方法
EP1468997A2 (fr) Formes polymorphes de maléate de rosiglitatone
US6436956B1 (en) Useful form of anhydrous paroxetine hydrochloride
AU2020412067A1 (en) Crystalline forms of (S) -1- (1-acryloylpyrrolidin-3-yl) -3- ( (3, 5-dimethoxyphenyl) ethynyl) -5- (methylamino) -1H-pyrazole-4-carboxamide
US7531551B2 (en) Polymorphs of cabergoline
KR100659927B1 (ko) 다형태를갖는독사조신메실레이트의새로운형태(제iii형)
KR100586350B1 (ko) (ｒ)-3-[[(4-플루오로페닐)술포닐]아미노]-1,2,3,4-테트라히드로-9ｈ-카르바졸-9-프로판산 (라마트로반)의열역학적으로 안정한 형태
JPH06192228A (ja) 結晶性（ｒ）−（−）−２−シクロヘプチル−ｎ−メチルスルフオニル−［４−（２−キノリニルメトキシ）−フエニル］−アセトアミド
US20050143445A1 (en) Novel crystalline forms of levetiracetam
AU2002333942B2 (en) Crystalline form of a phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same
US20090227645A1 (en) Pharmaceutical compositions of valdecoxib
WO2005023769A1 (fr) Procede pour l'elaboration de sels d'amlodipine
US5596109A (en) N-t-butyl-androst-3,5-diene-17β-carboxamide-3-carboxylic acid polymorph A
CA1096385A (fr) 5-(indol-3-ylmethylene)-1,3-dimethyl-2-methylimino-4- imidazolidinone
US5859266A (en) "N-T-butyl-androst-3-5-diene-17 β-carboxamide-3-carboxylic" acid polymorph A
SK65699A3 (en) Process for the preparation of nmda antagonists
EP3656768A1 (fr) Cristaux de beraprost-314d et méthodes pour leur préparation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued